SPL-707
CAS No. : 2195361-33-0
| Size | Price | Stock |
|---|---|---|
| 1mg | $320 | In-stock |
| 5mg | $780 | In-stock |
| 10mg | $1200 | In-stock |
| 25mg | $2040 | In-stock |
| 50mg | $3260 | In-stock |
| 100 mg | Get quote | |
| 200 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-111360 |
| M.Wt: | 505.54 |
| Formula: | C27H28FN5O4 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
SPL-707 is an orally active, selective signal peptide peptidase-like 2a (SPPL2a) inhibitor with an IC50 of 77 nM for hSPPL2a. SPL-707 inhibits γ-secretase (IC50=6.1 μM) and SPP (IC50=3.7 μM). SPL-707 has the potential for autoimmune diseases research by targeting B cells and dendritic cells[1].
IC50 & Target: IC50: 77 nM (SPPL2a), 6.1 μM (γ-secretase) and 3.7 μM (SPP)[1]
In Vitro: SPL-707 (Compound 40) inhibits mouse SPPL2a (IC50=0.18 μM), rat SPPL2a (IC50=0.056 μM) and human SPPL2a (IC50=0.16 μM), human SPPL2b (IC50=0.43 μM) by a high content imaging assay (HCA)[1].
In Vivo: SPL-707 (Compound 40; 3-30 mg/kg; orally; b.i.d.; for 11 days) leads to a reduction in B cells and myeloid dendritic cells without affecting γ-secretase activity[1].
SPL-707 (3 mg/kg of po and 1 mg/kg of iv) has a CL of 6 mL/min?kg, and an AUC of 8787 h?nM[1].
SPL-707 (1, 3 mg/kg; b.i.d.; first dose at 0 h, second dose at 8 h) achieves full inhibition of CD74/p8 processing in spleen in female Lewis rats[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- SPL-707
- Cat. No.:
- HY-111360
- Quantity:
Your information is safe with us.